Manganese-induced parkinsonism in methcathinone abusers: Bio-markers of exposure and follow-up

European Journal of Neurology

Volumn 20, Issue 6, 2013, Pages 915-920

  Sikk, K ^a   Haldre, S ^a   Aquilonius, S M ^b   Asser, A ^a   Paris, M ^c   Roose, Ä ^c   Petterson, J ^d   Eriksson, S L ^d   Bergquist, J ^d   Taba, P ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b UPPSALA UNIVERSITY   (Sweden)

^c North Estonia Medical Centre   (Estonia)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Ephedrone; Follow up; Manganism; Methcathinone; MRI hyperintensities; Parkinsonism

Indexed keywords

BIOLOGICAL MARKER; MANGANESE; METHCATHINONE;

ADULT; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CORPUS STRIATUM; DRUG EXPOSURE; ESTONIA; FEMALE; FOLLOW UP; HOEHN AND YAHR SCALE; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL; SCHWAB AND ENGLAND RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; ESTONIA; FEMALE; FOLLOW-UP STUDIES; HAIR; HUMANS; MALE; MANGANESE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; PROPIOPHENONES; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84877672962     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12088     Document Type: Article

References (27)

1. Sikk K, Taba P, Haldre S, et al. Irreversible motor impairment in young addicts-ephedrone, manganism or both? Acta Neurol Scand 2007; 115: 385-389.
2. De Bie RM, Gladstone RM, Strafella AP, Ko JH, Lang AE. Manganese-induced parkinsonism associated with methcathinone (ephedrone) abuse. Arch Neurol 2007; 64: 886-889.
3. Colosimo C, Guidi M. Parkinsonism due to ephedrone neurotoxicity: a case report. Eur J Neurol 2009; 16: e114-e115.
4. Varlibas F, Delipoyraz I, Yuksel G, Filiz G, Tireli H, Gecim NO. Neurotoxicity following chronic intravenous use of "Russian cocktail". Clin Toxicol (Phila) 2009; 47: 157-160.
5. Iqbal M, Monaghan T, Redmond J. Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report. J Med Case Rep 2012; 6: 52.
6. Meral H, Kutukcu Y, Atmaca B, Ozer F, Hamamcioglu K. Parkinsonism caused by chronic usage of intravenous potassium permanganate. Neurologist 2007; 13: 92-94.
7. Yildirim EA, Essizoglu A, Koksal A, Dogu B, Baybas S, Gokalp P. [Chronic manganese intoxication due to methcathinone (ephedron) abuse: a case report]. Turk Psikiyatri Derg 2009; 20: 294-298.
8. Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, Fahn S. Manganic encephalopathy due to "ephedrone" abuse. Mov Disord 2007; 22: 1337-1343.
9. Stepens A, Logina I, Liguts V, et al. A parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 2008; 358: 1009-1017.
10. Selikhova M, Fedoryshyn L, Matviyenko Y, et al. Parkinsonism and dystonia caused by the illicit use of ephedrine - a longitudinal study. Mov Disord 2008; 23: 2224-2231.
11. Koksal A, Baybas S, Sozmen V, et al. Chronic manganese toxicity due to substance abuse in Turkish patients. Neurol India 2012; 60: 224-227.
12. Fahn SER, Members of the UDC. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease Florham Park. NJ: Macmillan Health Care Information, 1987: 153-164.
13. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241-248.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
15. Huang CC, Lu CS, Chu NS, et al. Progression after chronic manganese exposure. Neurology 1993; 43: 1479-1483.
16. Huang CC, Chu NS, Lu CS, Chen RS, Calne DB. Long-term progression in chronic manganism: ten years of follow-up. Neurology 1998; 50: 698-700.
17. Huang CC, Chu NS, Lu CS, Chen RS, Schulzer M, Calne DB. The natural history of neurological manganism over 18 years. Parkinsonism Relat Disord 2007; 13: 143-145.
18. Kim Y, Kim JW, Ito K, et al. Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography. Neurotoxicology 1999; 20: 249-252.
19. Nelson K, Golnick J, Korn T, Angle C. Manganese encephalopathy: utility of early magnetic resonance imaging. Br J Ind Med 1993; 50: 510-513.
20. Pujol A, Pujol J, Graus F, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993; 43: 65-69.
21. Stepens A, Stagg CJ, Platkajis A, Boudrias MH, Johansen-Berg H, Donaghy M. White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome. Brain 2010; 133: 3676-3684.
22. Sikk K, Taba P, Haldre S, et al. Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol Scand 2010; 121: 237-243.
23. Herrero HE, Discalzi G, Valentini C, et al. Follow-up of patients affected by manganese-induced parkinsonism after treatment with CaNa2EDTA. Neurotoxicology 2006; 27: 333-339.
24. Shinotoh H, Snow BJ, Chu NS, et al. Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study. Neurology 1997; 48: 1053-1056.
25. Kessler KR, Wunderlich G, Hefter H, Seitz RJ. Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor density. Mov Disord 2003; 18: 217-218.
26. Guilarte TR, Burton NC, McGlothan JL, et al. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem 2008; 107: 1236-1247.
27. Guilarte TR, Chen MK, McGlothan JL, et al. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol 2006; 202: 381-390.